NCT01153542已完成1 期
An Open-Label Phase 1 Study to Examine the Effect of VX 770 on Desipramine in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- VX-770 and Desipramine pharmacokinetic parameters
研究概览
简要总结
The objective of this study is to evaluate the effects of VX-770 on Desipramine
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects must be male or female and between 18 and 55 years of age
- •Subject must have a body mass index (BMI) from 18 to 30 kg/m2
- •Subject must be judged to be in good health
排除标准
- •History of any illness that, in the opinion of the investigator or the subject's general practitioner, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject
- •Subjects who have human immunodeficiency virus, hepatitis C, or active hepatitis B
- •Female subjects and male subjects with female partner(s) who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of the last dose of study drug
研究组 & 干预措施
VX-770
Experimental
干预措施: VX-770 (Drug)
desipramine
Experimental
干预措施: VX-770 (Drug)
结局指标
主要结局
VX-770 and Desipramine pharmacokinetic parameters
时间窗: 3 weeks
次要结局
- Safety as measured by adverse events, vital signs, electrocardiograms (ECGs), and clinically significant laboratory assessments(3 weeks)
- Metabolites pharmacokinetic parameters in plasma(3 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770Cystic FibrosisNCT01060566Vertex Pharmaceuticals Incorporated24
已完成
1 期
Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy SubjectsIn Development for Cystic FibrosisNCT01208285Vertex Pharmaceuticals Incorporated24
进行中（未招募）
2 期
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPDChronic Obstructive Pulmonary DiseaseNCT06533553Areteia Therapeutics30
进行中（未招募）
1 期
A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative ColitisModerate to Severe Ulcerative ColitisNCT06693908Genentech, Inc.24
撤回
2 期
Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or DependenceBipolar I or II Depression and Alcohol Abuse or DependenceNCT00204503The University of Texas Medical Branch, Galveston